Avatrombopag in Primary Immune Thrombocytopenia (ITP) in Adults

The Institute of Hematology & Blood Diseases Hospital in China is conducting a single-centre, prospective study to evaluate the efficacy and safety of avatrombopag in adult ITP patients who do not respond well to eltrombopag or recombinant human thrombopoietin (rhTPO). Avatrombopag is a thrombopoietin receptor agonist used to stimulate the bone marrow to produce more platelets. Enrollment is restricted to 20 adults who are over the age of 18 years and have been diagnosed with chronic (primary) ITP with platelet counts less than 30,000 µL.



Status: Recruiting

back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo